MoonLake Immunotherapeutics Stock Drops on Secondary Share Offering
MoonLake Immunotherapeutics (NASDAQ: MLTX) experienced a nearly 6% decline in its stock price following an announcement of a secondary share offering. The company plans to raise between $180 million and $200 million, which will be used for the development and commercialization of sonelokimab, its late-stage autoimmune drug candidate.
Tickers: $MLTX
Topics: biotech equity financing share dilution